Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Regeneron | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Regeneron

Global EYLEA sales up 12% in the quarter to $1.3B

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron

1Q Revenues: $1.3 billion (+10%)

1Q Earnings: $249 million

Comments: Global EYLEA sales were up 12% in the quarter to $1.3 billion. Sales of EYLEA in the U.S. increased 9% to $854 million. Bayer commercializes EYLEA outside the U.S. Global sales of Praluent were $36 million, compared to $13 million in 1Q16. R&D expenses were $507 million in the quarter compared to $470 million in 1Q16. In the quarter, the company received U.S. FDA approval for Dupixent, a therapy for moderate-to-severe atopic dermatitis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters